What causes ohcm

What is Obstructive Hypertrophic Cardiomyopathy (OHCM)?

Obstructive hypertrophic cardiomyopathy (OHCM) is a chronic cardiovascular condition characterized by the abnormal thickening (hypertrophy) of the heart muscle, specifically the left ventricle and often the interventricular septum. This thickening is not caused by external factors like high blood pressure or valve disease, but rather by inherent defects in the heart muscle itself. In the obstructive form, the thickened septum bulges into the left ventricle, narrowing the outflow tract and impeding the efficient ejection of blood into the aorta during systole (heart contraction). This obstruction can significantly increase the workload of the heart and lead to a variety of symptoms.

What Causes OHCM?

The primary cause of hypertrophic cardiomyopathy (HCM), including its obstructive form, is genetic. It is an autosomal dominant inherited disorder, meaning that a person needs to inherit only one copy of the mutated gene from one parent to develop the condition. In approximately 50% of cases, affected individuals inherit the mutation from an affected parent. However, in about half of all diagnoses, the mutation occurs spontaneously (de novo) in the affected individual without a family history.

Genetic Basis of OHCM

The genetic mutations responsible for HCM typically affect the genes that code for sarcomeric proteins – the building blocks of the heart muscle cells (myocytes). These proteins are crucial for muscle contraction. The most commonly implicated genes include:

• MYH7: This gene codes for the beta-myosin heavy chain protein, a critical component of the contractile apparatus. Mutations in MYH7 are the most frequent cause of HCM, accounting for a significant percentage of familial cases.
• MYBPC3: This gene encodes cardiac myosin-binding protein C, another essential sarcomeric protein involved in regulating the interaction between actin and myosin during muscle contraction. Mutations in MYBPC3 are also very common, particularly in certain populations.
• Other Genes: While MYH7 and MYBPC3 are the most prevalent, mutations in other sarcomeric protein genes, such as TNNT2, TNNI3, TPM1, and MYL2, can also lead to HCM. The specific gene mutation can sometimes influence the severity and pattern of the heart muscle thickening, as well as the likelihood of obstruction.

These genetic alterations lead to disarray in the arrangement of heart muscle cells and the sarcomeres within them. This disorganization results in the characteristic thickening of the heart muscle, particularly the interventricular septum, which can become disproportionately thicker than the free wall of the left ventricle. This asymmetrical septal hypertrophy is a hallmark of HCM.

The Obstructive Component

In OHCM, the hypertrophy is often severe and predominantly affects the basal anterior septum. This thickened septum, along with systolic anterior motion (SAM) of the anterior mitral valve leaflet, contributes to the obstruction of blood flow. SAM occurs when the thickened septum and the enlarged mitral valve leaflet are drawn towards each other during systole, further narrowing the left ventricular outflow tract (LVOT). This dynamic obstruction can vary in severity depending on factors like heart rate, blood volume, and contractility.

Risk Factors and Progression

While genetics is the primary driver, certain factors can influence the expression and progression of OHCM:

• Inheritance Pattern: As an autosomal dominant trait, there is a 50% chance of passing the condition to offspring.
• Age: The condition can manifest at any age, from infancy to adulthood. Symptoms may worsen over time, although the disease course is highly variable.
• Environmental Factors: While not causative, factors like intense physical exertion in individuals with underlying HCM have been associated with an increased risk of adverse events, including sudden cardiac death.

Symptoms and Diagnosis

The symptoms of OHCM can vary widely and may include shortness of breath (especially during exertion), chest pain, palpitations, dizziness, fainting (syncope), and fatigue. In some individuals, the condition may be asymptomatic and discovered incidentally during an examination for other reasons or following an adverse event. Diagnosis typically involves electrocardiogram (ECG), echocardiogram (ultrasound of the heart), and often cardiac MRI or genetic testing.

Management and Outlook

Management strategies aim to relieve symptoms, prevent obstruction, and reduce the risk of complications like arrhythmias and sudden cardiac death. Treatment may include medications (beta-blockers, calcium channel blockers, antiarrhythmics), lifestyle modifications, and in severe cases, surgical myectomy or alcohol septal ablation to reduce the thickened muscle. Early diagnosis and appropriate management are crucial for improving the quality of life and prognosis for individuals with OHCM.